Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,407 across all filing types
Latest filing 2025-10-01 Declaration of Voting R…
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
Total Voting Rights
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a regulatory notification from AstraZeneca PLC regarding the total number of voting rights and issued share capital, filed in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. This type of disclosure is a standard regulatory requirement for companies listed on the London Stock Exchange to inform shareholders of the denominator for transparency calculations. It does not represent a change in shareholding (MRQ), a transaction in own shares (POS), or a capital change (SHA), but rather a periodic update of the total voting rights figure. As it is a standard regulatory announcement provided via RNS, it falls under the RNS category.
2025-10-01 English
Total voting rights
Regulatory Filings Classification · 98% confidence The document is a regulatory notification regarding the total number of voting rights and issued share capital, filed in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. This type of disclosure is a standard regulatory requirement for companies to inform shareholders of the denominator for calculating interest notifications. It does not represent a major shareholding change (MRQ), a share issue (SHA), or a transaction in own shares (POS), but rather a periodic update on capital structure for transparency purposes, which falls under the RNS category.
2025-10-01 English
ENHERTU IMPROVED IDFS IN EARLY BC IN DB-05
Regulatory Filings
2025-09-29 English
AZN HARMONISES LISTING STRUCTURE
Regulatory Filings
2025-09-29 English
6-K
Regulatory Filings
2025-09-29 English
Enhertu improved IDFS in early BC in DB-05
Earnings Release Classification · 100% confidence The document is a press release from AstraZeneca announcing positive high-level results from a Phase III clinical trial (DESTINY-Breast05). It details the trial's efficacy, safety profile, and future presentation plans at a medical congress. This type of announcement regarding clinical trial results is a standard regulatory disclosure for pharmaceutical companies, falling under the 'Regulatory Filings' category as it does not fit into specific financial reporting or corporate governance categories. Q3 2025
2025-09-29 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.